# A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies

> **NCT02571036** · PHASE1 · COMPLETED · sponsor: **Deciphera Pharmaceuticals, LLC** · enrollment: 282 (actual)

## Conditions studied

- Gastrointestinal Stromal Tumors
- Advanced Systemic Mastocytosis
- Advanced Cancers

## Interventions

- **DRUG:** DCC-2618
- **DRUG:** DCC-2618

## Key facts

- **NCT ID:** NCT02571036
- **Lead sponsor:** Deciphera Pharmaceuticals, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11
- **Primary completion:** 2022-04-29
- **Final completion:** 2022-04-29
- **Target enrollment:** 282 (ACTUAL)
- **Last updated:** 2023-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02571036

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02571036, "A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02571036. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*